Payload Information
General Information of This Payload
| Payload ID | PAY0KDADU |
|||||
|---|---|---|---|---|---|---|
| Name | Tolllike receptor 7 agonist |
|||||
| Synonyms |
Tolllike receptor 7 agonist
Click to Show/Hide
|
|||||
| Target(s) | Toll-like receptor 7 (TLR7) | |||||
| Structure |
|
|||||
| Formula | C20H27N5O |
|||||
| Isosmiles | CCCCCNc1nc(N)nc2ccn(Cc3ccc(C)cc3OC)c12 |
|||||
| InChI |
InChI=1S/C20H27N5O/c1-4-5-6-10-22-19-18-16(23-20(21)24-19)9-11-25(18)13-15-8-7-14(2)12-17(15)26-3/h7-9,11-12H,4-6,10,13H2,1-3H3,(H3,21,22,23,24)
|
|||||
| InChIKey |
YFZPFMRAWMWBDG-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
353.47 |
Polar area |
77.99 |
||
Complexity |
353.2215605 |
xlogp Value |
3.98092 |
|||
Heavy Count |
26 |
Rot Bonds |
8 |
|||
Hbond acc |
6 |
Hbond Donor |
2 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
NJH-395 [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
0.00%
|
|||
| Patients Enrolled |
Patients with nonbreast HER2+ advanced malignancies.
|
||||
| Administration Dosage |
5 dose cohorts (0.10-1.60 mg/kg).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03696771 | Phase Status | Phase 1 | ||
| Clinical Description |
A phase 1, multicenter, open-label dose finding study of NJH395, administered intravenously in patients with non-breast HER2+ advanced malignancies.
|
||||
References